Ignite Creation Date:
2025-12-25 @ 4:33 AM
Ignite Modification Date:
2026-02-21 @ 2:51 PM
Study NCT ID:
NCT01792518
Status:
COMPLETED
Last Update Posted:
2017-03-06
First Post:
2013-02-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069476', 'term': 'Linagliptin'}], 'ancestors': [{'id': 'D011687', 'term': 'Purines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D011799', 'term': 'Quinazolines'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clintriage.rdg@boehringer-ingelheim.com', 'phone': '1-800-243-0127', 'title': 'Boehringer Ingelheim, Call Center', 'organization': 'Boehringer Ingelheim'}, 'certainAgreement': {'otherDetails': "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From first drug administration until 28 days after the last drug administration, up to 240 days', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.', 'otherNumAtRisk': 178, 'otherNumAffected': 27, 'seriousNumAtRisk': 178, 'seriousNumAffected': 8}, {'id': 'EG001', 'title': 'Linagliptin 5 mg', 'description': 'Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.', 'otherNumAtRisk': 182, 'otherNumAffected': 39, 'seriousNumAtRisk': 182, 'seriousNumAffected': 17}], 'otherEvents': [{'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 13}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 24}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}], 'seriousEvents': [{'term': 'Acute myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cardiac failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Myocardial ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Sudden hearing loss', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Vestibular disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 2}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Gastrointestinal fistula', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pancreatitis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Abscess limb', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Arteriovenous graft site infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Kidney infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Post procedural infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Pyelonephritis acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Septic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Ankle fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Peripheral nerve injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Postpericardiotomy syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Myositis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Gastric cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cerebral haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Acute kidney injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Calculus urinary', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Aortic occlusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Necrosis ischaemic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 178, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 182, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '156', 'groupId': 'OG000'}, {'value': '161', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}, {'id': 'OG001', 'title': 'Linagliptin 5 mg', 'description': 'Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.63', 'spread': '0.06', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.60', 'ciLowerLimit': '-0.78', 'ciUpperLimit': '-0.43', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.09', 'estimateComment': 'Mean Difference (Final Values) is actually the Adjusted mean difference calculated as Linagliptin 5 mg minus Placebo.', 'groupDescription': 'Superiority of Linagliptin 5 mg vs. placebo: change in HbA1c is analysed using mixed model repeated measures (MMRM) approach. Model includes baseline HbA1c, baseline log10 (UACR), baseline HbA1c by visit and baseline log10 (UACR) by visit as linear covariates and treatment, visit, visit by treatment interaction as fixed effects.', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'The Unstructured covariance structure has been used to fit the mixed model', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': 'Change from baseline in Glycated haemoglobin (HbA1c) \\[%\\] after 24 weeks of treatment with double- blind trial medication. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest.', 'unitOfMeasure': 'Percentage of HbA1c', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS) - including all randomised patients who were treated with at least one dose of study drug, had a baseline HbA1c and a baseline Urinary albumin creatinine ratio (UACR), and at least one on treatment HbA1c or UACR assessment. Observed Case (OC): Values after the use of rescue medication were set to missing.'}, {'type': 'SECONDARY', 'title': 'The Time Weighted Average of Percentage Change From Baseline in UACR During the Course of 24 Weeks of Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '173', 'groupId': 'OG000'}, {'value': '178', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}, {'id': 'OG001', 'title': 'Linagliptin 5 mg', 'description': 'Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.9487', 'spread': '0.06', 'groupId': 'OG000', 'lowerLimit': '0.8857', 'upperLimit': '1.0162'}, {'value': '0.8902', 'spread': '0.06', 'groupId': 'OG001', 'lowerLimit': '0.8318', 'upperLimit': '0.9526'}]}]}], 'analyses': [{'pValue': '0.1954', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of adjusted geometric means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.94', 'ciLowerLimit': '0.85', 'ciUpperLimit': '1.03', 'estimateComment': 'Ratio of relative change for Linagliptin 5 mg over placebo is presented.', 'groupDescription': 'Superiority of Linagliptin 5 mg vs. placebo: change in UACR is analysed using analysis of covariance model. Model includes baseline HbA1c and baseline log10 (UACR) as linear covariates and treatment as fixed effect.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': 'The time weighted average of percentage change from baseline in UACR (mg/g creatinine) during the course of 24 weeks of treatment. The term "baseline" for UACR refers to the geometric mean of UACR values measured at Visits 2 and 3. The number of participants analysed displays the number of participants with available data at the timepoint of interest. The Least Squares Means are adjusted geometric means.', 'unitOfMeasure': 'mg/g creatinine', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS) - including all randomised patients who were treated with at least one dose of study drug, had a baseline HbA1c and a baseline Urinary albumin creatinine ratio (UACR), and at least one on treatment HbA1c or UACR assessment. Last Observation Carried Forward (LOCF).'}, {'type': 'SECONDARY', 'title': 'The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '156', 'groupId': 'OG000'}, {'value': '162', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}, {'id': 'OG001', 'title': 'Linagliptin 5 mg', 'description': 'Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.35', 'spread': '1.92', 'groupId': 'OG000'}, {'value': '-4.98', 'spread': '1.89', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.3306', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.63', 'ciLowerLimit': '-7.95', 'ciUpperLimit': '2.68', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.70', 'estimateComment': 'Mean Difference (Final Values) is actually the Adjusted mean difference calculated as Linagliptin 5 mg minus Placebo.', 'groupDescription': 'Change in eGFR is analysed using mixed model repeated measures (MMRM) approach. Model includes baseline HbA1c, baseline log10 (UACR), baseline eGFR, baseline HbA1c by visit, baseline log10 (UACR) by visit and baseline eGFR by visit as linear covariates and treatment, visit, visit by treatment interaction as fixed effects.', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'The Unstructured covariance structure has been used to fit the mixed model', 'testedNonInferiority': False}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and 24 weeks', 'description': 'The change from baseline in estimated glomerular filtration rate (eGFR) as assessed by chronic kidney disease epidemiology collaboration (CKD-EPI) equation (cystatin C) after 24 weeks of treatment. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest. This outcome measure is a secondary safety endpoint.', 'unitOfMeasure': 'milliliter/minute/1.73 square metre', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Treated Set'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}, {'id': 'FG001', 'title': 'Linagliptin 5 mg', 'description': 'Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '178'}, {'groupId': 'FG001', 'numSubjects': '182'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '170'}, {'groupId': 'FG001', 'numSubjects': '175'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Other Reason', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}], 'recruitmentDetails': '360 patients were randomised and treated (Placebo: 178 patients, Linagliptin: 182 patients.)', 'preAssignmentDetails': 'Randomized, double-blind, placebo controlled, parallel group study to evaluate glycemic and renal efficacy of once daily administration of Linagliptin 5 milligram (mg) for 24 weeks in type 2 diabetes patients, with micro- or macroalbuminuria on top of current treatment with Angiotensin Converting Enzyme inhibitor or Angiotensin Receptor Blocker'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '178', 'groupId': 'BG000'}, {'value': '182', 'groupId': 'BG001'}, {'value': '360', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Patients received 1 matching placebo tablet to Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}, {'id': 'BG001', 'title': 'Linagliptin 5 mg', 'description': 'Patients received 1 tablet of Linagliptin 5 mg, administered orally, once every day for 24 weeks during the double blind treatment period.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '60.1', 'spread': '9.3', 'groupId': 'BG000'}, {'value': '61.0', 'spread': '10.0', 'groupId': 'BG001'}, {'value': '60.6', 'spread': '9.6', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Gender', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '65', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '131', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '113', 'groupId': 'BG000'}, {'value': '116', 'groupId': 'BG001'}, {'value': '229', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Treated Set (TS) - including all patients treated with at least one dose of randomised trial medication.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 360}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-01', 'completionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-01-13', 'studyFirstSubmitDate': '2013-02-14', 'resultsFirstSubmitDate': '2016-11-08', 'studyFirstSubmitQcDate': '2013-02-14', 'lastUpdatePostDateStruct': {'date': '2017-03-06', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-01-13', 'studyFirstPostDateStruct': {'date': '2013-02-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2017-03-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2015-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment', 'timeFrame': 'Baseline and 24 weeks', 'description': 'Change from baseline in Glycated haemoglobin (HbA1c) \\[%\\] after 24 weeks of treatment with double- blind trial medication. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest.'}], 'secondaryOutcomes': [{'measure': 'The Time Weighted Average of Percentage Change From Baseline in UACR During the Course of 24 Weeks of Treatment', 'timeFrame': 'Baseline and 24 weeks', 'description': 'The time weighted average of percentage change from baseline in UACR (mg/g creatinine) during the course of 24 weeks of treatment. The term "baseline" for UACR refers to the geometric mean of UACR values measured at Visits 2 and 3. The number of participants analysed displays the number of participants with available data at the timepoint of interest. The Least Squares Means are adjusted geometric means.'}, {'measure': 'The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment', 'timeFrame': 'Baseline and 24 weeks', 'description': 'The change from baseline in estimated glomerular filtration rate (eGFR) as assessed by chronic kidney disease epidemiology collaboration (CKD-EPI) equation (cystatin C) after 24 weeks of treatment. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest. This outcome measure is a secondary safety endpoint.'}]}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'referencesModule': {'references': [{'pmid': '30632692', 'type': 'DERIVED', 'citation': 'Siwy J, Klein T, Rosler M, von Eynatten M. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial. Proteomics Clin Appl. 2019 Mar;13(2):e1800144. doi: 10.1002/prca.201800144. Epub 2019 Jan 28.'}, {'pmid': '28636754', 'type': 'DERIVED', 'citation': 'Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31.'}, {'pmid': '26224765', 'type': 'DERIVED', 'citation': 'Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial. Diab Vasc Dis Res. 2015 Nov;12(6):455-62. doi: 10.1177/1479164115579002. Epub 2015 Jul 28.'}]}, 'descriptionModule': {'briefSummary': 'Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n* Diagnosis of type 2 diabetes mellitus\n* Glycosylated Hemoglobin (HbA1c) between 6.5 and 10% (inclusive)\n* Current therapy with ACEi or ARB at stable dose for 10 weeks\n* Urinary albumin-to-creatinine ratio (UACR): 30-3000 mg/g creatinine documented in the previous 12 months or detected at Screening.\n* Estimated Glomerular Filtration Rate (eGFR) greater than 30 ml/min.\n* Age between 18 and 80 years.\n\nExclusion criteria:\n\n* Dual or triple blockade of the Renin Angiotensin System (RAS)\n* Uncontrolled hyperglycaemia\n* Mean arterial blood pressure \\> 110 mmHg\n* Known hypersensitivity or allergy to the investigational product, or their excipients (including matching placebos).\n* Treatment with a glitazone within 6 months prior to informed consent.\n* Treatment with a DiPeptidyl-Peptidase 4 (DPP-4) inhibitor, a Glucagon Like Peptide-1 (GLP-1) agonist, a Sodium/Glucose coTransporter 2 (SGLT2) inhibitor, a dopamine-agonist, a bile-acid sequestrant a short acting (prandial) insulin or premixed insulin within 10 weeks prior to informed consent.\n* Treatment with anti-obesity drugs 10 weeks prior to informed consent.\n* Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.\n* Current treatment with systemic steroids (glucocorticoids) at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.\n* Participation in another trial with an investigational drug within 2 months prior to informed consent.'}, 'identificationModule': {'nctId': 'NCT01792518', 'briefTitle': 'MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)', 'orgStudyIdInfo': {'id': '1218.89'}, 'secondaryIdInfos': [{'id': '2012-002603-17', 'type': 'EUDRACT_NUMBER', 'domain': 'EudraCT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'linagliptin 5mg', 'description': 'linagliptin 5 mg once daily', 'interventionNames': ['Drug: Linagliptin 5mg']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'placebo', 'description': 'matching placebo for linagliptin dose once daily', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Placebo', 'type': 'DRUG', 'armGroupLabels': ['placebo']}, {'name': 'Linagliptin 5mg', 'type': 'DRUG', 'armGroupLabels': ['linagliptin 5mg']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'city': 'North Hollywood', 'state': 'California', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 34.17223, 'lon': -118.37897}}, {'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'city': 'Evansville', 'state': 'Indiana', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.97476, 'lon': -87.55585}}, {'city': 'Flint', 'state': 'Michigan', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'city': 'Jackson', 'state': 'Mississippi', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 32.29876, 'lon': -90.18481}}, {'city': 'Asheboro', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.70791, 'lon': -79.81364}}, {'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'city': 'Knoxville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.96064, 'lon': -83.92074}}, {'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'city': 'Victoria', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.4359, 'lon': -123.35155}}, {'city': 'Mount Pearl', 'state': 'Newfoundland and Labrador', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 47.51659, 'lon': -52.78135}}, {'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'city': 'Mississauga', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.5789, 'lon': -79.6583}}, {'city': 'Sarnia', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 42.97866, 'lon': -82.40407}}, {'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Waterloo', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.4668, 'lon': -80.51639}}, {'city': 'Gentofte Municipality', 'country': 'Denmark', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 55.74903, 'lon': 12.54601}}, {'city': 'Hillerød', 'country': 'Denmark', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 55.92791, 'lon': 12.30081}}, {'city': 'Silkeborg', 'country': 'Denmark', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 56.1697, 'lon': 9.54508}}, {'city': 'Slagelse', 'country': 'Denmark', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 55.40276, 'lon': 11.35459}}, {'city': 'Kerava', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 60.40338, 'lon': 25.105}}, {'city': 'Oulu', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 65.01236, 'lon': 25.46816}}, {'city': 'Tampere', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'city': 'Turku', 'country': 'Finland', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'city': 'Bersée', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.47978, 'lon': 3.14765}}, {'city': 'Bourg-des-Comptes', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 47.92955, 'lon': -1.74298}}, {'city': 'Grenoble', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.17869, 'lon': 5.71479}}, {'city': 'Le Creusot', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 46.80714, 'lon': 4.41632}}, {'city': 'Marseille', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Saint-Mandé', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 48.83864, 'lon': 2.41579}}, {'city': 'Vénissieux', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 45.69706, 'lon': 4.88593}}, {'city': 'Vieux-Condé', 'country': 'France', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.45944, 'lon': 3.56738}}, {'city': 'Aschaffenburg', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 49.97704, 'lon': 9.15214}}, {'city': 'Aßlar', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.59163, 'lon': 8.46273}}, {'city': 'Dresden', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'city': 'Flörsheim', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.01311, 'lon': 8.42779}}, {'city': 'Pirna', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.95843, 'lon': 13.93702}}, {'city': 'Schweinfurt', 'country': 'Germany', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 50.04937, 'lon': 10.22175}}, {'city': 'Aoba-ku,Sendai,Miyagi', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'Chiyoda-ku,Tokyo', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Cyuo-ku,Tokyo', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Kita-ku, Osaka, Osaka', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'Shimizu-ku,Shizuoka city,Shizuoka', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'Suita,Osaka', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'Teine-ku,Sapporo,Hokkaido', 'country': 'Japan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Cebu City, Philippines', 'country': 'Philippines', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'Pasig City, Philippines', 'country': 'Philippines', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'San Juan City, Philippines', 'country': 'Philippines', 'facility': 'Boehringer Ingelheim Investigational Site'}, {'city': 'Goyang', 'country': 'South Korea', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 36.21689, 'lon': 127.19731}}, {'city': 'Jinju', 'country': 'South Korea', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.19278, 'lon': 128.08472}}, {'city': 'Seongnam', 'country': 'South Korea', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 35.54127, 'lon': 127.39683}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Wŏnju', 'country': 'South Korea', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 37.35139, 'lon': 127.94528}}, {'city': "L'Hospitalet de Llobregat", 'country': 'Spain', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Pozuelo de Alarcón', 'country': 'Spain', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'city': 'San Sebastián de los Reyes', 'country': 'Spain', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 40.55555, 'lon': -3.62733}}, {'city': 'Valencia', 'country': 'Spain', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Changhua', 'country': 'Taiwan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 24.0692, 'lon': 120.5512}}, {'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'city': 'New Taipei City', 'country': 'Taiwan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 25.06199, 'lon': 121.45703}}, {'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'city': 'Tainan', 'country': 'Taiwan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'city': 'Hanoi, Vietnam', 'country': 'Vietnam', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 21.0245, 'lon': 105.84117}}, {'city': 'Ho Chi Minh City', 'country': 'Vietnam', 'facility': 'Boehringer Ingelheim Investigational Site', 'geoPoint': {'lat': 10.82302, 'lon': 106.62965}}], 'overallOfficials': [{'name': 'Boehringer Ingelheim', 'role': 'STUDY_CHAIR', 'affiliation': 'Boehringer Ingelheim'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}